Jie Xue

Jie Xue

Auto-generated profile, based on publicly available information

Jie Xue

Department of Neurology, Yangpu Hospital Tongji University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2013 in Journal of Pharmacy & Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
RCRong Chen
Rong Chen
JXJie Xue
Jie Xue
MXMeilin Xie
Meilin Xie
PURPOSE. Our previous studies have demonstrated that osthole, an active constituent isolated from the fruit of Cnidium monnieri (L.) Cusson, can prevent isoprenaline-induced myocardial fibrosis in mice, but the underlying mechanism is still unclear. METHODS. The mouse cardiac fibroblasts (CFs) stimulated with angiotensin II (Ang II) were cultured and treated with different concentrations of osthole. The mRNA expressions of peroxisome proliferator-activated receptor (PPAR) α/γ, transforming growth factor β1 (TGF-β1), and matrix metalloproteinase (MMP)-2/9 were detected by reverse transcription polymerase chain reaction method, and the protein expressions of nuclear factor-κB (NF-κB) and TGF-β1 were detected by Western blot method, respectively. RESULTS. Following treatment of cells with osthole at 2.5, 5, 10 and 20 μg/mL, the NF-κB and TGF-β1 expressions were dose-dependently decreased, while the expressions of PPARα/γ and MMP-2/9 were dose-dependently increased. After the cells were preincubated with PPARα antagonist (MK886) or/and PPARγ antagonist (GW9662), the inhibitions of osthole on the NF-κB and TGF-β1 expressions were decreased or completely halted and the increment of osthole on the MMP-2/9 expressions were also decreased or completely cancelled. CONCLUSION. Osthole could inhibit the NF-κB and TGF-β1 expressions by activation of PPARα/γ, and subsequently enhance the MMP-2/9 expressions in cultured CFs, and these effects of osthole may play the beneficial roles in the prevention and treatment of myocardial fibrosis. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.

13 December 2017 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
XLXian‐Mei Li
Xian‐Mei Li
PJPing‐Ping Jin
Ping‐Ping Jin
JXJie Xue
Jie Xue
JCJie Chen
Jie Chen
QCQin‐Fen Chen
Qin‐Fen Chen
BSBei Shao
Bei Shao
Objective: The role ofsLOX‐1 in acute ischemic stroke still remains unclear. This study aims to demonstrate the value ofsLOX‐1 in evaluating degrees of intracranial artery stenosis and to predict prognosis in stroke.Methods: Two hundred and seventy‐two patients were included in this study and basic data were collected within 72 hr on admission. We assessed the association betweensLOX‐1 levels and stroke conditions in one‐year duration. After adjusting for potential confounders, regression analyses were performed.Results: We found thatsLOX‐1 levels were increased significantly in severe patients compared to the mild stroke group (p = .011). After adjusting confounders,sLOX‐1 was associated with a poor functional outcome in patients with an adjustedORof 2. 946 (95%CI, 1.788–4.856,p < .001). There was also positive correlation betweensLOX‐1 levels and the degrees of intracranial artery stenosis in the different groups (p = .029).Conclusions: Our study demonstrated thatsLOX‐1 levels could be used to evaluate the severity of stroke and the degrees of intracranial artery stenosis. Furthermore,sLOX‐1 could be exploited to predict the long‐term functional outcome of stroke.

12 April 2017 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
JXJie Xue
Jie Xue
YLYuanshao Lin
Yuanshao Lin
WHWensi Huang
Wensi Huang
XCXiaoli Chen
Xiaoli Chen
QLQian Li
Qian Li
BSBei Shao
Bei Shao
Background: Although a number of studies have reported the role of an increased left atrial (LA) size on stroke, limited data are collected about the relationship between LA enlargement and recurrent ischemic stroke in the Chinese population. Our aim was to assess the association of LA size with the risk of stroke recurrence, particularly with recurrent cardioembolic or cryptogenic stroke in ischemic stroke patients.Methods: The study recruited 313 consecutive patients with acute first‐ever ischemic stroke. Echocardiographic LA diameter was measured and indexed by height and body surface area separately. The endpoint was recurrent ischemic stroke. Cox proportional hazard models were used to examine the association of LA size with total recurrent ischemic stroke and recurrent cardioembolic or cryptogenic stroke while adjusting for baseline demographics characteristics, clinical factors, echocardiographic left ventricular ejection fraction, and medication.Results: Over a median follow‐up period of 1.63 years, 47 recurrent ischemic strokes (21 were cardioembolic or cryptogenic) occurred. In a multivariate model adjusted for potential confounders, compared with the bottom tertiles of LA diameter indexed to height (LA diameter/H), the top tertile of LA diameter/H was significantly associated with the total recurrent ischemic stroke (adjusted HR 3.610, 95% CI 1.870–6.967, p < .001) and the composite of recurrent cardioembolic or cryptogenic stroke (adjusted HR 5.673, 95% CI 1.780–18.084, p = .003). Results were similar when LA diameter indexed to body surface area (LA diameter/BSA) was involved in the analysis.Conclusion: LA size is an independent predictor of total recurrent ischemic stroke and the composite of recurrent cardioembolic or cryptogenic stroke.

20 March 2024 in World Neurosurgery
Verified
Journal Article
Closed access
JXJie Xue
Jie Xue
XZXiao-Guang Zhang
Xiao-Guang Zhang
DZDong Zhang
Dong Zhang
LHLiang Hu
Liang Hu
XXXu-Shen Xu
Xu-Shen Xu
YYYun-Hua Yue
Yun-Hua Yue